---
title: "Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of \"Buy\" from Analysts"
description: "Alto Neuroscience, Inc. (NYSE:ANRO) has received an average \"Buy\" rating from six analysts. The stock has a 12-month target price of $35.00. Insider activity includes an insider buying 12,069 shares o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/211256476.md"
published_at: "2024-08-10T05:37:27.000Z"
---

# Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Buy" from Analysts

> Alto Neuroscience, Inc. (NYSE:ANRO) has received an average "Buy" rating from six analysts. The stock has a 12-month target price of $35.00. Insider activity includes an insider buying 12,069 shares of the stock. The company operates as a clinical-stage biopharmaceutical company.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been given an average rating of "Buy" by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.00.

Get **Alto Neuroscience** alerts:

A number of analysts recently commented on ANRO shares. William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a report on Wednesday, June 12th. Rodman & Renshaw initiated coverage on Alto Neuroscience in a report on Friday, June 21st. They set a "buy" rating and a $43.00 target price for the company.

**View Our Latest Analysis on Alto Neuroscience**

## Alto Neuroscience Stock Down 8.0 %

Shares of NYSE ANRO opened at $8.37 on Friday. Alto Neuroscience has a one year low of $8.15 and a one year high of $24.00. The company has a current ratio of 26.02, a quick ratio of 26.02 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average price of $12.07.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.30). Equities research analysts expect that Alto Neuroscience will post -2.93 EPS for the current year.

## Insider Activity

In other Alto Neuroscience news, insider Adam Savitz bought 12,069 shares of the business's stock in a transaction dated Tuesday, July 9th. The shares were purchased at an average price of $12.60 per share, with a total value of $152,069.40. Following the completion of the purchase, the insider now owns 36,920 shares in the company, valued at approximately $465,192. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

## Institutional Trading of Alto Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $113,000. Federated Hermes Inc. grew its position in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock worth $128,000 after purchasing an additional 3,000 shares during the period. Bank of New York Mellon Corp acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $252,000. University of Texas Texas AM Investment Managment Co. acquired a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $340,000. Finally, Bowie Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the 2nd quarter valued at about $462,000.

## About Alto Neuroscience

(Get Free Report

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

## Further Reading

-   Five stocks we like better than Alto Neuroscience
-   3 Fintech Stocks With Good 2021 Prospects
-   The Cannabis Sector: Profitability Takes Center Stage
-   Health Care Stocks Explained: Why You Might Want to Invest
-   Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
-   Consumer Discretionary Stocks Explained
-   Buy the Dip in e.l.f. Beauty: Analysts Point to a New High

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Kamala Harris’ Woke Politics Could Lead to 50% Stock Collapse (From Paradigm Press) (Ad)## Should you invest $1,000 in Alto Neuroscience right now?

Before you consider Alto Neuroscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.

While Alto Neuroscience currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [ANRO.US - Alto Neuroscience](https://longbridge.com/en/quote/ANRO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 沃尔玛四季度财报超预期但盈利指引不及预期，CEO 称 “美国低收入家庭只能勉强维持生计” | 沃尔玛 Q4 营收超预期，新财年盈利指引（每股 2.75-2.85 美元）远低于市场预期的 2.96 美元，显示通胀压力下消费者支出不确定性犹存，拖累股价下跌 1.38%。财报印证 K 型” 分化：高收入家庭驱动增长，低收入群体 “钱包吃紧 | [Link](https://longbridge.com/en/news/276398633.md) |
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/en/news/276396515.md) |
| GRAIL｜8-K：2025 财年 Q4 营收 43.6 百万美元超过预期 |  | [Link](https://longbridge.com/en/news/276379877.md) |
| 最高法裁决后特朗普动用替补选择：加征 10% 全球关税 | 美国总统特朗普在最高法院裁决后宣布将加征 10% 的全球关税，以补救被推翻的关税措施。根据《1974 年贸易法》第 122 条款，现有的关税将全面生效。最高法院裁定特朗普政府的部分关税措施缺乏法律授权。市场风险提示，投资需谨慎。 | [Link](https://longbridge.com/en/news/276477629.md) |
| 学习英伟达刺激芯片销售，AMD 为 “AI 云” 借款做担保 | AMD 为扩大市场份额祭出金融 “狠招”！为初创公司 Crusoe 的 3 亿美元购芯贷款提供担保，承诺在其无客户时 “兜底” 租用芯片。这一复刻英伟达 “租卡云” 路径的策略虽能短期推高销量，但也令 AMD 在 AI 需求放缓时面临更大的 | [Link](https://longbridge.com/en/news/276401504.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
